AGENDA | APRIL 8 | 1:00 PM EDT
1:00 - 1:05 PM
Welcome & Opening Remarks
Presented By:
William J. Link, PhD, Managing Partner - Flying L Partners
1:05 - 1:15 PM
Anterior Market Overview
Presented By:
William Trattler, MD, President - Center for Excellence In Eye Care
1:15 - 2:20 PM
Company Showcase
Tarsier Pharma | Daphne Haim-Langford, PhD - Founder & CEO
Eyevance Pharmaceuticals | Steve Babineaux, MS, RPh - Senior Medical Science Liaison, Ophthalmology - Santen
Voptica | Pablo Artal, PhD - Founder & CEO
Visus Therapeutics | Ben Bergo - CEO
Tarsus Pharmaceuticals | Aziz Mottiwala - Chief Commercial Officer
LayerBio | Kenneth Mandell, MD, PhD - CEO
ViaLase | Tibor Juhasz - CEO
AcuFocus | Yari Mitchell - Chief Business Development Officer
LENSAR | Nick Curtis - CEO
2:20 - 3:20 PM
Corporate Pipeline Presentations
Bausch + Lomb
Chuck Hess - VP & General Manager, US Surgical
Robert Kissling, MD - VP, Medical and Clinical Affairs
Allergan
Michael Robinson, MD - VP, Global Therapeutic Area Head, Eye Care
Johnson & Johnson Vision
Patricia Piers - Senior Director, Global IOL R&D
MK Raheja, PhD - Head, Surgical Vision R&D
Nancy Sabin - Senior Director, Global Strategic Marketing
Novartis
Aileen Wrynn - Program Head, Ocular Surface Disease
Mark Wuttke - Program Head, Refractive
3:20 - 4:10 PM
Clinical Panel Discussion
Panelists:
Rosa Braga-Mele MD, MEd, FRCSC, Professor of Ophthalmology - University of Toronto
Cathleen M. McCabe, MD, Chief Medical Officer - Eye Health America /
Medical Director - The Eye Associates
William Wiley, MD, Medical Director - Cleveland Eye Clinic
Robert Weinstock, MD, Director of Cataract and Refractive Surgery - Eye Institute of West Florida/Weinstock Laser Eye Center / Associate Clinical & Fellowship Director of the Refractive Surgery Fellowship Program - The Eye Institute of West Florida
Moderated By:
William Trattler, MD, President - Center for Excellence In Eye Care
4:10 - 5:00 PM
Virtual Networking
PROUDLY SPONSORED BY:
Gold Sponsor
Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, is one of the world's best-known and most respected health care brands, solely focused on protecting, enhancing and restoring people's eyesight.
Silver Sponsors
Aerie Pharmaceuticals
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, ocular surface diseases and retinal diseases. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie is expanding globally, with offices in Europe and Japan, and a manufacturing facility in Ireland. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% are approved in the EU. A Phase 3 study of netarsudil ophthalmic solution is underway in Japan, in collaboration with Santen. Aerie is also pursuing additional candidates in ophthalmology, including a Phase 2b dry eye program with AR-15512 (TRPM8 agonist), and two clinical-stage retina programs, AR-1105 (dexamethasone) Sustained Release Implant and AR-13503 (Rho kinase/Protein kinase C inhibitor) Sustained Release Implant. Aerie continues to investigate assets from its proprietary library of small-molecule multi-kinase inhibitors.
Allergan
Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics.
Novartis
Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products.
Promedica International
Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California. We have successfully been providing exceptional value to our clients for over 30 years in clinical trial project management, site recruitment and management, clinical study monitoring, data management, biostatistics, medical writing and GCP auditing.
Bronze Sponsors
Eyevance Pharmaceuticals
Eyevance Pharmaceuticals was born out of a desire to revolutionize the eye care industry. Co-Founders Jerry St. Peter and Jason Werner had worked together in the ophthalmic space for many years leading up to their life-changing decision to form Eyevance. They noticed a therapeutic segment of the industry was largely underserved and immediately saw an opportunity to not only occupy the space, but to step up and lead it. Eyevance was founded on the concept of thinking, acting, and doing differently. We see opportunities where others don’t. We think outside the box, problem solving and innovating in unconventional ways. Everything we do centers around our customers. Built on innovative and impactful products, Eyevance is a force within ocular surface disease states.
Johnson & Johnson Vision
At Johnson & Johnson Vision, we have a bold ambition: to change the trajectory of eye health. Through our operating companies, we've developed solutions for every stage of life-to help people see better, connect better and live better. We partner with eye care professionals to provide some of the world's leading products and technologies to address refractive error, cataracts, dry eye, and beyond. We are committed to using our reach and size for good and strive to put quality eye care within reach of everyone, everywhere.
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a number of diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis and Meibomian Gland Disease.
MEDIA PARTNERS:
